Controversial New Alzheimer’s Drug Approved Despite Reservations
Follow via Flickr Link: https://www.flickr.com/photos/alzmglc/15311519476/in/photolist-pk2xi7-p5zz1T-pn36eW-pk2z4G-pn4Zzt-p5yHLJ-p5yCyQ-p5yy7H-p5yKrY-p5zBtP-pn2YxE-pn4BVM-p5ztkA-pmMonT-p5ziQo-bxQfpz-pmMxTM-p5zXeR-p5zbib-p5zQFk-pn3m45-pk2Tsf-p5zB8E-pn4N6g-4eGjGS-CFX1-pk2JQf-WfWjgu-pk2Lc3-3hQn2G-4kkzZx-6DojR2-51m44-7rJbFK-9YAmBr-fkWSC9-44Aksc-nSqng6-GAH7BD-j1M1Sk-gv1YhP-6Doi7x-3xK9k-6DoitF-dwaKm8-fkWSGw-6DoiYK-6DssxN-MhcFWN-o17RFw
The U.S. Food and Drug Administration has approved the first new drug for Alzheimer’s disease in 20 years, but some doctors, including one at UAB, warned patients’ families not to expect much from the drug any time soon.
The drug, aducanumab, is expected to help slow the progression of the disease, but not to improve current memory impairments, according to a release from the University of Alabama at Birmingham. The university’s Division of Memory Disorders and the Alzheimer’s Disease Center have been involved in clinical trials of aducanumab for the past five years.
“The approval of the first disease-modifying therapy is a milestone for our field and a result of years of intense research. However, it must be understood that [aducanumab] is not expected to restore memory or reverse the symptoms of Alzheimer’s disease,” said Dr. David Geldmacher, professor of neurology at UAB and clinical core director of the center. “Instead, it is expected to slow the worsening of the disease. [Aducanumab] is likely the beginning of a new era in treating AD, but not the end of the story.”
Geldmacher said it would be some time before the drug is widely available, not all patients will be eligible to receive it, and many patients, especially with advanced disease, are not likely to see improvement from it.
The FDA approved the drug despite opposition from an independent advisory committee and some Alzheimer’s experts who said there was not enough evidence the drug helps patients, according to several news reports, including from the Associated Press.
The FDA did require the drugmaker, Biogen, to conduct another study to determine whether it benefits patients, and it could pull the drug from the market if its effectiveness is not proven.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
Trump was ‘very involved’ in Kennedy Center Honorees selection, vetoed ‘wokesters’
Trump announced the Kennedy Center Honorees on Wednesday. They are Sylvester Stallone, Gloria Gaynor, Kiss, George Strait and Michael Crawford.
A lock of hair may have just changed what we know about life in the Incan Empire
Inca society kept records by encoding information into knotted cords called khipu. A new analysis of hair woven into these cords suggests this record-keeping was practiced by commoners as well as elites.
Zelenskyy: Trump supports ceasefire and security guarantees for Ukraine at Putin summit
European leaders held a high-stakes meeting Wednesday with President Trump, Vice President JD Vance, Ukraine's Zelenskyy, NATO's chief, and European leaders ahead of Friday's US Russia summit.
A dogged reporter takes on a mysterious cabal in ‘The Diary of Lies’
Philip Miller's sinister thriller is set in a Great Britain that's lost its bearings. But even when she's terrified, fictional journalist Shona Sandison will always risk everything to get the story.
In 1985, famine led to Live Aid and a U.S. alert plan. Trump froze it. Now it’s back
It's the 40th anniversary of the superstar concert to raise money for an Ethiopian famine — and of the creation of a U.S. program called FEWS NET to prevent future famines.
With ‘Golden’ topping ‘Ordinary,’ a K-pop girl group hits No. 1 for the first time
The members of HUNTR/X — the fictional K-pop group made up of nonfictional singers EJAE, Audrey Nuna and REI AMI — have just become the first women K-pop artists ever to hit No. 1.
